Market Report, "Australia Pharmaceuticals & Healthcare Report Q3 2011", published

June 17, 2011 - PRLog -- BMI View: Australia's challenging economic situation is affecting its pharmaceutical market. The acceptance of expensive patented drugs by the three main stakeholders - payers, prescribers and patients - is being superseded by the pragmatic delivery of medical services. We expect to see the formalisation of the practice of health economics, the swifter uptake of generic drugs and the increased involvement of the private sector in pharmaceutical purchasing.

Headline Expenditure Projections

* Pharmaceuticals: AUD12.41bn (US$11.30bn) in 2010 to AUD12.38bn (US$10.46bn) in 2011; -0.2% in local currency terms and -7.4% in US dollar terms. Our forecast has been revised up slightly from Q211 due to the receipt of more reliable historic market data.
 * Healthcare: AUD123bn (US$112bn) in 2010 to AUD128bn (US$109bn) in 2011; +4.3% in local currency terms and -3.1% in US dollar terms. Our forecast has been revised down from Q211 due to analyst intervention.
 * Medical devices: AUD5.33bn (US$4.85bn) in 2010 to AUD5.46bn (US$4.62bn) in 2011; +2.4% in local currency terms and -4.9% in US dollar terms. Our forecast has been revised down from Q211 due to analyst intervention.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/169856_australia_pharmaceutica...
------------------------------------------------------------


Business Environment Rating: Australia's Q311 Pharmaceutical Business Environment Rating (BER) score (63.7) and regional ranking (third) is unchanged compared with the previous quarter. Its Country Rewards score (80) is the highest in Asia Pacific, primarily due to significant urbanisation and the high prevalence of elderly people. Australia also posts the highest score in Asia Pacific for Country Risks, which comprises economic structure, policy continuity, bureaucracy, legal framework and corruption.

Key Trends & Developments

* In November 2011, a number of Australian Senators and Members of Parliament initiated a private members Bill, which will significantly undermine the protection afforded to innovative biopharmaceutical medicines. Specifically, the legislation declares that all biological materials cannot be covered by intellectual property (IP) protection.
 * The Therapeutic Goods Administration's Half-Yearly Performance Report revealed that only 574 new clinical trials were initiated in Australia in 2010, the lowest number since 2001. The report also found a 13% year-on-year (y-o-y) decline in the number of clinical trials for the three consecutive years from 2007.


BMI Economic View: The Australian economy experienced a slowdown in Q310, growing by a sluggish 0.2% q-o-q (seasonally-adjusted) from a revised 1.1% recorded in the preceding quarter. The recent deceleration in Australia's headline real GDP growth was consistent with our below-consensus growth forecast of 2.8% for 2010. Indeed, we believe the recent tightening in borrowing costs and weakening consumer confidence will act as key headwinds in 2011. In addition, the country also suffered major destruction and disruptions of economic activity, due to flooding in parts of Queensland and Victoria in January, followed by Cyclone Yasi in the north in February. In short, the resulting impact on the domestic economy should contribute to the slowdown in economic growth to 2.4% and 2.3% in 2011 and 2012 respectively.

BMI Political View: The Australian Labor Party (ALP) government faces a number of key political challenges over the next two years, such as the 30% Mineral Resource Rent Tax (MRRT), Emissions Trading Scheme (ETS), and flood levy resulting from the Queensland floods. These issues serve as potential stumbling blocks to the ALP administration given that it only controls a one-seat majority in the lower house. While we maintain our view that the ALP will successfully complete its three-year term, the risks to our outlook have risen substantially in 2011. Should the incumbent lose power, the rise of the business-friendly opposition Liberal-National Coalition may serve to benefit Australian corporations.

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Australia Pharmaceuticals And Healthcare Industry SWOT
- Australia Political SWOT
- Australia Economic SWOT
- Australia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific - Pharmaceutical Business Environment Ratings, Q311
- Rewards
- Risks
Australia - Market Summary
Regulatory Regime
- OTC Switching Climate
- Regional Regulatory Harmonisation
- Recent Regulatory Developments
- Intellectual Property Issues
- Trade Agreements
- Pricing and Reimbursement
- Table: Historical PBS Co-payments
- Price Cuts
- Recent Pricing and Reimbursement Developments
- Table New PBS Formularies
Industry Trends and Developments
- Epidemiology
- Communicable Diseases
- Mental Health Issues
- E-Health
- Prescribing Patterns
- Biotechnology and Research
- Recent Developments in the Biotechnology Sector
- Clinical Trials
- Recent Developments in the Clinical Trials Industry
- Medical Device Market
- Table Examples Of Medical Devices Classifications
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Australia - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
-

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1698...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.